Literature DB >> 11080826

The MHC class I heavy chain is a common target of the small proteins encoded by the 3' end of HTLV type 1 and HTLV type 2.

J M Johnson1, J C Mulloy, V Ciminale, J Fullen, C Nicot, G Franchini.   

Abstract

Human T cell leukemia/lymphotropic virus types 1 and 2 are two immunologically and phylogenetically related retroviruses that differ in their pathogenicity in vivo. The overall genetic structure of HTLV-1 and -2 is similar. Each contains a unique region at the 3' end of the genome, designated the pX region. p12(I) is a membrane-associated protein encoded by the open reading frame I (ORF I) region of HTLV-1, which lies within the pX region. A corresponding protein, p10(I) is encoded by the ORF I region of HTLV-2 and an additional protein, p11(V), is encoded by ORF V, which overlaps the HTLV-2 ORF I region. As with HTLV-1, the small proteins encoded by the pX region of HTLV-2 appear to be dispensable for viral replication and cellular transformation in vitro. However, the small open reading frames of both viruses are important for viral replication in vivo, which suggests they may play an important role during the viral life cycle. This study was undertaken to investigate and compare the cellular targets of the p10(I), p11(V), and p12(I) putative proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080826     DOI: 10.1089/08892220050193308

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR.

Authors:  Min Li; Patrick L Green
Journal:  J Virol Methods       Date:  2007-03-06       Impact factor: 2.014

2.  The SCHOOL of nature: IV. Learning from viruses.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-10

Review 3.  Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.

Authors:  Nancy Van Prooyen; Vibeke Andresen; Heather Gold; Izabela Bialuk; Cynthia Pise-Masison; Genoveffa Franchini
Journal:  Mol Aspects Med       Date:  2010-07-29

4.  First report of HTLV-1 truncated p12 protein in Brazil.

Authors:  Carolina Rosadas; Ana C P Vicente; Louise Zanella; Mauro J Cabral-Castro; José M Peralta; Marzia Puccioni-Sohler
Journal:  Virulence       Date:  2016-12-14       Impact factor: 5.882

5.  Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin.

Authors:  W Ding; B Albrecht; R Luo; W Zhang; J R Stanley; G C Newbound; M D Lairmore
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1.

Authors:  Brian M Kurtz; Lauren B Singletary; Sean D Kelly; Arthur R Frampton
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Human T lymphotropic virus type 1 accessory protein p12I modulates calcium-mediated cellular gene expression and enhances p300 expression in T lymphocytes.

Authors:  Amrithraj Nair; Bindhu Michael; Hajime Hiraragi; Soledad Fernandez; Gerold Feuer; Kathleen Boris-Lawrie; Michael Lairmore
Journal:  AIDS Res Hum Retroviruses       Date:  2005-04       Impact factor: 2.205

Review 8.  Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis.

Authors:  Björn Albrecht; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

Review 9.  Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.

Authors:  Michael Bindhu; Amrithraj Nair; Michael D Lairmore
Journal:  Front Biosci       Date:  2004-09-01

10.  Subcellular localization of the bovine leukemia virus R3 and G4 accessory proteins.

Authors:  Laurent Lefèbvre; Vincenzo Ciminale; Alain Vanderplasschen; Donna D'Agostino; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.